GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

K2 Black Panther deal with Poland to strengthen South Korea’s position in European defense market, says GlobalData

South Korea’s ambitions to become a major global defense exporter have taken a significant leap forward with the recent announcement of a $6.5 billion contract to supply 180 K2 Black Panther main battle tanks to Poland. The deal confirms Seoul as a trusted supplier of modern, North Atlantic Treaty Organization (NATO)‑compatible equipment at a time […]
Read more

Hypersonic missiles to help Japan counter escalating security challenges in Indo-Pacific region, says GlobalData

The deployment of the Hyper Velocity Guided Projectile (HVGP) will be a significant shift in Japan’s defense strategy, which has historically committed to a purely defensive posture. Japan is now poised to integrate this hypersonic missile into its force structure to conduct offensive operations when required. The advancements in missile technology by China and North […]
Read more

Challenges mount for big pharma in China as vaccine sales plummet, says GlobalData

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China’s vaccine market, as regulatory scrutiny, domestic competition, and changing consumer behaviors disrupt a once-thriving sector. Major players like Merck & Co. and GSK are re-evaluating their strategies in light of these developments, says GlobalData, a leading data and analytics company. GlobalData’s Q2 2025 Emerging Market […]
Read more

Vutrisiran to change ATTR-CM treatment paradigm in Europe, says GlobalData

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. It can cause ATTR-cardiomyopathy (ATTR-CM) or ATTR-polyneuropathy (ATTR-PN). As effective treatments for ATTR-CM are still limited, Alnylam Pharmaceuticals’ drug vutrisiran is expected to change ATTR-CM treatment paradigm upon market launch in Europe, […]
Read more

Nontuberculous mycobacteria market to reach $4.6 billion in 7MM in 2033, forecasts GlobalData

The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 8.8% from $2.0 billion in 2023 to $4.6 billion in 2033, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast”, reveals that […]
Read more

Diagnosed prevalent cases of multiple sclerosis to increase by 0.19% AGR in 7MM during 2024-34, forecasts GlobalData

The diagnosed prevalent cases of multiple sclerosis (MS) in the seven major markets (7MM*) are projected to increase from 1.61 million in 2024 to 1.64 million in 2034 at an annual growth rate (AGR) of negative 0.19%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Multiple Sclerosis Epidemiology Analysis and Forecast to […]
Read more

UK health & beauty specialists lose out to discounters in value for money rankings, finds GlobalData

UK health & beauty specialists are struggling to compete with low-priced discounters, as consumers are not recognizing the additional value for money that comes from their better ranges, product quality, and service. With personal finances still recovering from the impact of inflationary pressure, consumers still prefer to shop at discounters for essentials, according to GlobalData, […]
Read more

Japan cardiac marker tests market to reach $19 million by 2036, forecasts GlobalData

The increasing global burden of cardiovascular diseases (CVD), driven by lifestyle-related risk factors and limited access to early diagnostics, has accelerated the demand for advanced, data-driven medical solutions. Against this backdrop, Japan’s cardiac marker tests market value is forecast to reach $19 million by 2036, according to GlobalData, a leading data and analytics company. GlobalData’s […]
Read more
1 36 37 38 39 40 136